Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446132 · ClinicalTrials.gov registry record · Phase 3
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,197
- Enrollment target
NCT02446132 is a Phase 3 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1,197 participants.
The verdict
NCT02446132, a Phase 3 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,197 participants
- Enrollment target
Study Summary
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
Interventions
- DRUG AVP-786
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,197 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446132
The ClinicalTrials.gov registry entry for NCT02446132 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVP-786 is the first listed.
NCT02446132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446132 about?
NCT02446132 is a clinical study titled "Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type". This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
What is the current status of trial NCT02446132?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,197 participants. The study started on 2015-11-13. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT02446132?
The interventions under investigation include: AVP-786 (DRUG).
Who is sponsoring clinical trial NCT02446132?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.